



NAVANA PHARMA

NAVANA PHARMACEUTICALS PLC.

Corporate Office:

99 Gulshan Avenue, Rupayan Golden Age, 6th Floor, Plot-6, Block-CWN(C), Dhaka-1212.

PRICE SENSITIVE INFORMATION

This is for kind information to all valued shareholders of Navana Pharmaceuticals PLC. and stakeholders that the Board of Directors of the company in its 67th meeting held on 3rd June, 2026 ended at 3.40 p.m. has considered and approved, among others, the Un-Audited Financial Statements for the third quarter (Q3) period ended on March 31, 2026 and took the following Price Sensitive Decisions: -

1. Comparative Statement of the Un-Audited Financial Statements for the Third Quarter (Q3) of the financial year 2025-2026, for the period ended 31 March 2026:

Sl. No	Particulars	01.07.2025-31.03.2026	01.07.2024-31.03.2025	01.01.2026-31.03.2026	01.01.2025-31.03.2025
i	Earnings Per Share (EPS)	4.59	3.49	1.22	1.01
		4.55 (Diluted)	N/A	1.20 (Diluted)	N/A
ii	Net Operating Cash Flow Per Share (NOCFPS)	15.44	10.22	N/A	N/A
		As at 31.03.2026	As at 30.06.2025		
iii	Net Asset Value (NAV)	5,320,201,576	4,864,919,142	N/A	N/A
iv	Net Asset Value Per Share	49.53	45.29	N/A	N/A

Notes:

❖ **Reasons of significant deviation in Earning Per Share (EPS) and Net Operating Cash Flows Per share (NOCFPS) During the reporting periods:**

- > EPS : Increment of Earnings per Share in the reporting period by 31.52% because of growth of Sales Revenue as well as optimum cost management policy.
- > NOCFPS: Net Operating Cash Flow per Share (NOCFPS) has increased to Tk. 15.44 from Tk. 10.22, due to cash received from the customers was higher than the cash payment for operation in the reporting period.

- ❖ In compliance with the Dhaka & Chittagong Stock Exchange (Listing) Regulation, 2015, the company will publish the Un-Audited Financial Statements for the third quarter (Q3) period ended on March 31, 2026 in two widely circulated daily newspapers (one in Bengali and otherone in English) and also in an online news portal. The Un-Audited Financial Statements for the third quarter (Q3) in details will be available in the website (**www.navanapharma.com**) of the company.

2. The Company has decided to proceed with a Foreign Loan Facilities for EUR 26,610,000.00 for 12 years from AKA Ausfuhrkredit-Gesellschaft mbH, Frankfurt, Germany, the sole arranger of which is KGMC Financial Service, Bangladesh. The Company has decided to avail the aforesaid facilities for expansion of its production facilities. The proposed financing shall remain subject to final approval from the concerned regulatory authorities & completion of due diligence.

Dated: June 03, 2026

By order of the Board

sd/-

Lorens Shamol Mollick FCS
Company Secretary